DK2363414T3 - Site-directed modification of FVIII - Google Patents

Site-directed modification of FVIII Download PDF

Info

Publication number: DK2363414T3
Authority: DK; Denmark
Prior art keywords: fviii; site; directed modification; modification; directed
Prior art date: 2004-11-12

Application number

DK11153300.6T

Other languages

Danish (da)

Inventor

Clark Q Pan

John E Murphy

Jonathan S Strauss

Hendri Tjandra

Jianmin Chen

Thomas Barnett

Deqian Wamg

Baisong Mei

Liang Tang

Original Assignee

Bayer Healthcare Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-11-12

Filing date

2005-11-14

Publication date

2022-08-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36337298&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2363414(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-11-14 Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc

2022-08-08 Application granted granted Critical

2022-08-08 Publication of DK2363414T3 publication Critical patent/DK2363414T3/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Hematology (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Gastroenterology & Hepatology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Toxicology (AREA)
Diabetes (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Orthopedics, Nursing, And Contraception (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Materials For Medical Uses (AREA)
Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)

DK11153300.6T 2004-11-12 2005-11-14 Site-directed modification of FVIII DK2363414T3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US62727704P	2004-11-12	2004-11-12
EP05849392.5A EP1824988B1 (en)	2004-11-12	2005-11-14	Site-directed modification of fviii

Publications (1)

Publication Number	Publication Date
DK2363414T3 true DK2363414T3 (en)	2022-08-08

Family

ID=36337298

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DK11153300.6T DK2363414T3 (en)	2004-11-12	2005-11-14	Site-directed modification of FVIII
DK05849392.5T DK1824988T3 (en)	2004-11-12	2005-11-14	LOCATION-SPECIFIC MODIFICATION OF FVIII
DK11153297.4T DK2371856T3 (en)	2004-11-12	2005-11-14	Site-directed modifikation af FVIII

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
DK05849392.5T DK1824988T3 (en)	2004-11-12	2005-11-14	LOCATION-SPECIFIC MODIFICATION OF FVIII
DK11153297.4T DK2371856T3 (en)	2004-11-12	2005-11-14	Site-directed modifikation af FVIII

Country Status (32)

Country	Link
US (4)	US7632921B2 (en)
EP (9)	EP2371856B1 (en)
JP (5)	JP2008524117A (en)
KR (7)	KR101468345B1 (en)
CN (6)	CN105753968A (en)
AU (1)	AU2005304622B2 (en)
BE (1)	BE2019C523I2 (en)
BR (2)	BR122016022033B8 (en)
CA (1)	CA2586379C (en)
CY (3)	CY1119292T1 (en)
DK (3)	DK2363414T3 (en)
ES (4)	ES2930159T3 (en)
FR (1)	FR19C1031I2 (en)
HN (1)	HN2007015683A (en)
HR (2)	HRP20180481B1 (en)
HU (5)	HUE059193T2 (en)
IL (3)	IL182903A (en)
LT (5)	LT1824988T (en)
LU (1)	LUC00118I2 (en)
MA (1)	MA29663B1 (en)
MX (3)	MX350293B (en)
NL (1)	NL300989I2 (en)
NO (3)	NO20210454A1 (en)
NZ (1)	NZ555032A (en)
PH (2)	PH12014500352B1 (en)
PL (3)	PL2371856T3 (en)
PT (4)	PT2363414T (en)
RU (1)	RU2423380C2 (en)
SI (4)	SI2371856T1 (en)
UA (1)	UA95225C2 (en)
WO (1)	WO2006053299A2 (en)
ZA (1)	ZA200703696B (en)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2338333B1 (en)	2003-04-09	2017-09-06	ratiopharm GmbH	Glycopegylation methods and proteins/peptides produced by the methods
WO2005012484A2 (en)	2003-07-25	2005-02-10	Neose Technologies, Inc.	Antibody-toxin conjugates
US20080305992A1 (en)	2003-11-24	2008-12-11	Neose Technologies, Inc.	Glycopegylated erythropoietin
AU2005260763B2 (en) *	2004-06-30	2011-12-22	Nektar Therapeutics	Polymer-factor IX moiety conjugates
WO2006010143A2 (en)	2004-07-13	2006-01-26	Neose Technologies, Inc.	Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
EP1814573B1 (en)	2004-10-29	2016-03-09	ratiopharm GmbH	Remodeling and glycopegylation of fibroblast growth factor (fgf)
PT2363414T (en)	2004-11-12	2022-08-04	Bayer Healthcare Llc	Site-directed modification of fviii
JP4951527B2 (en)	2005-01-10	2012-06-13	バイオジェネリックスアーゲー	GlycoPEGylated granulocyte colony stimulating factor
US9187546B2 (en)	2005-04-08	2015-11-17	Novo Nordisk A/S	Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
JP5335422B2 (en)	2005-06-17	2013-11-06	ノボノルディスクヘルスケアアクチェンゲゼルシャフト	Selective reduction and derivatization of engineered proteins containing at least one unnatural cysteine
US20070105755A1 (en)	2005-10-26	2007-05-10	Neose Technologies, Inc.	One pot desialylation and glycopegylation of therapeutic peptides
US7855279B2 (en)	2005-09-27	2010-12-21	Amunix Operating, Inc.	Unstructured recombinant polymers and uses thereof
US20090048440A1 (en)	2005-11-03	2009-02-19	Neose Technologies, Inc.	Nucleotide Sugar Purification Using Membranes
RU2008145084A (en) *	2006-05-24	2010-06-27	Ново Нордиск Хелс Кеа Аг (Ch)	ANALOGUES OF FACTOR IX HAVING A LONG-TERM HALF-TIME IN VIVO
US20080242607A1 (en)	2006-07-21	2008-10-02	Neose Technologies, Inc.	Glycosylation of peptides via o-linked glycosylation sequences
JP2010505874A (en)	2006-10-03	2010-02-25	ノヴォノルディスクアー／エス	Purification method for polypeptide conjugates
EP3323430A1 (en)	2006-12-15	2018-05-23	Baxalta GmbH	Factor viia-(poly)sialic acid conjugate having prolonged in vivo half-life
DK2144923T3 (en)	2007-04-03	2013-05-13	Biogenerix Ag	METHODS OF TREATMENT WITH USING GLYCOPEGYLATED G-CSF
CA2690611C (en)	2007-06-12	2015-12-08	Novo Nordisk A/S	Improved process for the production of nucleotide sugars
AU2008323768A1 (en) *	2007-11-09	2009-05-14	Baxter Healthcare S.A.	Modified recombinant Factor VIII and von Willebrand Factor and methods of use
JP5619630B2 (en)	2008-02-27	2014-11-05	ノボ・ノルデイスク・エー／エス	Binding factor VIII molecule
WO2009140598A1 (en) *	2008-05-16	2009-11-19	Bayer Healthcare Llc	Targeted coagulation factors and method of using the same
BRPI0913374A2 (en) *	2008-06-04	2015-11-24	Bayer Healthcare Llc	fviii muteins for treatment of von willebrand disease
PL2291523T3 (en)	2008-06-24	2015-05-29	Csl Behring Gmbh	Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
WO2010019263A2 (en) *	2008-08-15	2010-02-18	Genzyme Corporation	Soluble flt constructs for treating cancers
KR20110071012A (en) *	2008-10-17	2011-06-27	백스터 인터내셔널 인코포레이티드	Modified blood factors that include low levels of water soluble polymers
KR20110093775A (en) *	2008-11-03	2011-08-18	바이엘 헬스케어 엘엘씨	How to treat hemophilia
EP2368124A4 (en) *	2008-11-24	2012-09-19	Bayer Healthcare Llc	Method of determining pegylated blood coagulation factor activity in a silica-based activated partial thromboplastin time assay
US20120121613A1 (en) *	2009-01-19	2012-05-17	Bayer Healthcare Llc	Protein conjugate having an endopeptidase- cleavable bioprotective moiety
DK2393828T3 (en)	2009-02-03	2017-01-23	Amunix Operating Inc	Extended recombinant polypeptides and compositions comprising same
US20110046060A1 (en)	2009-08-24	2011-02-24	Amunix Operating, Inc.,	Coagulation factor IX compositions and methods of making and using same
WO2010102886A1 (en) *	2009-02-19	2010-09-16	Novo Nordisk A/S	Modification of factor viii
CA2755395C (en) *	2009-03-20	2015-02-24	Hanmi Holdings Co., Ltd.	Method for preparing a site-specific physiologically active polypeptide conjugate
US20120142593A1 (en) *	2009-03-24	2012-06-07	Bayer Healthcare Llc	Factor VIII Variants and Methods of Use
ES2590679T3 (en)	2009-07-27	2016-11-23	Lipoxen Technologies Limited	Glycopolyallylation of proteins other than blood coagulation proteins
DK2459224T3 (en)	2009-07-27	2016-07-25	Baxalta GmbH	Blodstørkningsproteinkonjugater
US8809501B2 (en)	2009-07-27	2014-08-19	Baxter International Inc.	Nucleophilic catalysts for oxime linkage
US8642737B2 (en)	2010-07-26	2014-02-04	Baxter International Inc.	Nucleophilic catalysts for oxime linkage
ES2856055T3 (en)	2009-07-27	2021-09-27	Baxalta GmbH	Glycopolysialylation of proteins other than blood clotting proteins
JP5903048B2 (en)	2009-12-06	2016-04-13	バイオジェンヘモフィリアインコーポレイテッド	Factor VIII-Fc chimeric and hybrid polypeptides and methods of use thereof
US8765432B2 (en)	2009-12-18	2014-07-01	Oligasis, Llc	Targeted drug phosphorylcholine polymer conjugates
CN105524164A (en)	2010-02-16	2016-04-27	诺沃—诺迪斯克有限公司	Factor VIII molecules with reduced VWF binding
EP2536399B1 (en) *	2010-02-21	2019-11-20	Bayer HealthCare LLC	Method for activation and conjugation of biomolecules
DK2558538T3 (en)	2010-04-15	2019-08-05	Kodiak Sciences Inc	Zwitterion-containing polymers with high molecular weight
GB201007356D0 (en)	2010-04-30	2010-06-16	Leverton Licence Holdings Ltd	Conjugated factor VIIa
GB201007357D0 (en) *	2010-04-30	2010-06-16	Leverton Licence Holdings Ltd	Conjugated factor VIII
EP3508573A1 (en) *	2010-07-09	2019-07-10	Bioverativ Therapeutics Inc.	Systems for factor viii processing and methods thereof
MX351220B (en) *	2010-11-05	2017-10-05	Baxalta GmbH	A new variant of antihemophilic factor viii having increased specific activity.
EP2651433A1 (en) *	2010-12-16	2013-10-23	Novo Nordisk A/S	Aqueous factor viii solution
WO2012087838A1 (en)	2010-12-22	2012-06-28	Baxter International Inc.	Materials and methods for conjugating a water soluble fatty acid derivative to a protein
CA2836478A1 (en) *	2011-05-27	2012-12-06	Baxter International Inc.	Therapeutic protein conjugated to water-soluble polymers via reduced cysteine sulfhydryl group
US9486507B2 (en)	2011-06-10	2016-11-08	Biogen Ma Inc.	Pro-coagulant compounds and methods of use thereof
US9382305B2 (en)	2011-07-01	2016-07-05	Bayer Intellectual Property Gmbh	Relaxin fusion polypeptides and uses thereof
ES2913994T3 (en)	2011-07-08	2022-06-07	Bioverativ Therapeutics Inc	Chimeric and hybrid Factor VIII polypeptides, and methods of use thereof
RU2017101333A (en)	2011-09-23	2018-12-19	Ново Нордиск А/С	NEW GLUCAGON ANALOGUES
KR20130049671A (en) *	2011-11-04	2013-05-14	한미사이언스 주식회사	Method for preparation of biological active polypeptide conjugate
US10370430B2 (en) *	2012-02-15	2019-08-06	Bioverativ Therapeutics Inc.	Recombinant factor VIII proteins
PL2814502T3 (en)	2012-02-15	2018-02-28	Csl Behring Gmbh	Von willebrand factor variants having improved factor viii binding affinity
LT2814840T (en)	2012-02-15	2020-02-25	Bioverativ Therapeutics Inc.	Factor viii compositions and methods of making and using same
EP2666782A1 (en)	2012-05-22	2013-11-27	Imnate Sarl	Coagulation factor VIII with reduced immunogenicity.
WO2013185113A1 (en)	2012-06-08	2013-12-12	Biogen Idec Ma Inc.	Procoagulant compounds
WO2014008480A2 (en)	2012-07-06	2014-01-09	Biogen Idec Ma Inc.	Cell line expressing single chain factor viii polypeptides and uses thereof
HK1213767A1 (en)	2012-10-18	2016-07-15	Bioverativ Therapeutics Inc.	Methods of using a fixed dose of a clotting factor
EP3446700A1 (en)	2012-10-30	2019-02-27	Bioverativ Therapeutics Inc.	Methods of using fviii polypeptide
JP6330026B2 (en)	2013-03-15	2018-05-23	バイオベラティブセラピューティクスインコーポレイテッド	Factor VIII polypeptide preparation
SG11201505926VA (en)	2013-03-15	2015-09-29	Biogen Ma Inc	Factor ix polypeptide formulations
KR20150132449A (en) *	2013-03-15	2015-11-25	바이엘 헬스케어 엘엘씨	Recombinant factor viii formulations
RS59124B1 (en)	2013-04-18	2019-09-30	Novo Nordisk As	Stable, protracted glp-1/glucagon receptor co-agonists for medical use
EP2796145B1 (en)	2013-04-22	2017-11-01	CSL Ltd.	A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
TW201519900A (en) *	2013-04-28	2015-06-01	Bayer Healthcare Llc	Compositions and methods for inducing immune tolerance to coagulation factor proteins
EP3033098B1 (en)	2013-08-14	2022-06-22	Bioverativ Therapeutics Inc.	Recombinant factor viii proteins
TW202003554A (en)	2013-08-14	2020-01-16	美商百歐維拉提夫治療公司	Factor VIII-XTEN fusions and uses thereof
US10702608B2 (en)	2013-09-08	2020-07-07	Kodiak Sciences Inc.	Factor VIII zwitterionic polymer conjugates
WO2015059121A1 (en) *	2013-10-22	2015-04-30	Dbv Technologies	Method of treating haemophilia by inducing tolerance to blood factors
EP3065769A4 (en)	2013-11-08	2017-05-31	Biogen MA Inc.	Procoagulant fusion compound
RU2546297C1 (en) *	2013-11-19	2015-04-10	Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук	Agent improving rheological properties of blood
EP4332839A3 (en)	2013-12-06	2024-06-05	Bioverativ Therapeutics Inc.	Population pharmacokinetics tools and uses thereof
JP6778111B2 (en) *	2014-01-20	2020-10-28	オクタファルマ・アーゲー	A method for producing Factor VIII with an improved ratio of FVIII: C / FVIII: Ag
KR102567586B1 (en)	2014-02-04	2023-08-16	바이오젠 엠에이 인코포레이티드	Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
WO2015132724A1 (en)	2014-03-05	2015-09-11	Pfizer Inc.	Improved muteins of clotting factor viii
SG11201607642RA (en)	2014-03-24	2016-10-28	Biogen Ma Inc	Lyophilized factor ix formulations
WO2015154090A1 (en) *	2014-04-04	2015-10-08	Bloodworks	Routine laboratory and point-of-care (poc) testing for hemostasis
KR20160144429A (en)	2014-04-10	2016-12-16	바이엘 헬쓰케어 엘엘씨	Compounded media powder formulation and method of preparation of liquid medium for cell culture
US10570184B2 (en)	2014-06-04	2020-02-25	Novo Nordisk A/S	GLP-1/glucagon receptor co-agonists for medical use
EP3164150B1 (en)	2014-07-02	2020-11-04	CSL Behring Lengnau AG	Modified von willebrand factor
MA40864A (en)	2014-10-31	2017-09-05	Biogen Ma Inc	HYPOTAURINE, GABA, BETA-ALANINE AND CHOLINE FOR THE REGULATION OF THE ACCUMULATION OF RESIDUAL BY-PRODUCTS IN MAMMAL CELL CULTURE PROCESSES
US11155601B2 (en)	2015-03-06	2021-10-26	CSL Behring Lengnau AG	Modified von Willebrand factor having improved half-life
CA2986626A1 (en)	2015-05-22	2016-12-01	Csl Behring Recombinant Facility Ag	Truncated von willebrand factor polypeptides for treating hemophilia
CN107810194B (en)	2015-05-22	2021-10-08	康诺贝林伦瑙有限公司	Method for preparing modified von willebrand factor
AU2016301303B2 (en)	2015-08-03	2021-10-07	Bioverativ Therapeutics Inc.	Factor IX fusion proteins and methods of making and using same
US9849125B1 (en)	2015-11-03	2017-12-26	Banner Lifie Sciences LLC	Anti-overingestion dosage forms
BR112018013861A2 (en)	2016-01-07	2018-12-18	Csl Behring Recombinant Facility Ag	polypeptide, complex, pharmaceutical composition, methods for treating a blood clotting disorder, for producing a polypeptide and dimer of a polypeptide, for increasing factor viii half life and for increasing dimerization of said polypeptide, use of a polypeptide, kit pharmaceutical, plasmid or vector, and host cell
CA3008448A1 (en)	2016-01-07	2017-07-13	Csl Behring Recombinant Facility Ag	Mutated von willebrand factor
US20230151078A1 (en) *	2016-06-24	2023-05-18	Mogam Instiitute For Biomedical Research	Recombinant single-chain fviii and chemical conjugate thereof
KR20190073576A (en)	2016-11-11	2019-06-26	체에스엘 베링 렝나우 아게	A cut von Willebrand factor polypeptide for extravascular administration in the treatment or prevention of blood clotting disorders
CA3043250A1 (en)	2016-11-11	2018-05-17	CSL Behring Lengnau AG	Truncated von willebrand factor polypeptides for treating hemophilia
WO2018093766A1 (en)	2016-11-16	2018-05-24	Bayer Healthcare Llc	Red blood cell targeted factor viii and method of using the same
BR112019011198A2 (en)	2016-12-02	2019-12-17	Bioverativ Therapeutics Inc	methods of inducing immune tolerance to coagulation factors
WO2018102743A1 (en)	2016-12-02	2018-06-07	Bioverativ Therapeutics Inc.	Methods of treating hemophilic arthropathy using chimeric clotting factors
EP3576762A1 (en)	2017-01-31	2019-12-11	Bioverativ Therapeutics Inc.	Factor ix fusion proteins and methods of making and using same
US10335375B2 (en)	2017-05-30	2019-07-02	Patheon Softgels, Inc.	Anti-overingestion abuse deterrent compositions
KR20190086269A (en) *	2018-01-12	2019-07-22	재단법인 목암생명과학연구소	Long-acting recombinant glycoproteins and menufacturing method thereof
PL3793588T3 (en)	2018-05-18	2025-09-01	Bioverativ Therapeutics Inc.	Methods of treating hemophilia a
EP4041312A4 (en)	2019-10-10	2023-12-20	Kodiak Sciences Inc.	Methods of treating an eye disorder
WO2021091881A1 (en) *	2019-11-04	2021-05-14	The Trustees Of Columbia University In The City Of New York	High concentration cell penetrating caspase inhibitor conjugates compositions and methods thereof
CN114828870A (en) *	2019-12-06	2022-07-29	费城儿童医院	Compositions and methods for modulating factor VIII function

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS59172425A (en) *	1983-03-18	1984-09-29	Nippon Chemiphar Co Ltd	Novel blood coagulation factor derivative, its preparation and blood coagulation promoting agent containing the same
US7138505B1 (en)	1984-01-12	2006-11-21	Novartis Vaccines And Diagnostics, Inc.	Factor VIII:C nucleic acid molecules
US4970300A (en)	1985-02-01	1990-11-13	New York University	Modified factor VIII
US5451521A (en)	1986-05-29	1995-09-19	Genetics Institute, Inc.	Procoagulant proteins
US5422260A (en)	1986-05-29	1995-06-06	Genetics Institute, Inc. -Legal Affairs	Human factor VIII:c muteins
US5171844A (en)	1987-06-12	1992-12-15	Gist-Brocades N.W.	Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US6346513B1 (en)	1987-06-12	2002-02-12	Baxter Trading Gmbh	Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
EP0294910B1 (en)	1987-06-12	1996-09-11	Immuno Ag	Novel proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
AU2473388A (en) *	1987-11-16	1989-06-22	Scripps Clinic And Research Foundation	Treatment of factor viii inhibitors
US5166322A (en)	1989-04-21	1992-11-24	Genetics Institute	Cysteine added variants of interleukin-3 and chemical modifications thereof
SE465222C5 (en)	1989-12-15	1998-02-10	Pharmacia & Upjohn Ab	A recombinant human factor VIII derivative and process for its preparation
US5766897A (en)	1990-06-21	1998-06-16	Incyte Pharmaceuticals, Inc.	Cysteine-pegylated proteins
US6376463B1 (en)	1992-04-07	2002-04-23	Emory University	Modified factor VIII
US6037452A (en)	1992-04-10	2000-03-14	Alpha Therapeutic Corporation	Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
KR100303872B1 (en)	1992-10-02	2001-11-22	크리스터 발스트룀, 프레드릭 베르그, 하랄트 알름	Compositions containing coagulation factor formulations, methods for their preparation and use of surfactants as stabilizers
AU6029594A (en)	1993-01-15	1994-08-15	Enzon, Inc.	Factor viii - polymeric conjugates
SE504074C2 (en)	1993-07-05	1996-11-04	Pharmacia Ab	Protein preparation for subcutaneous, intramuscular or intradermal administration
EP0730660A4 (en)	1993-10-29	1998-02-25	Incyte Pharma Inc	Chimeric proteins including protease nexin-1 variants
IL113010A (en)	1994-03-31	1999-10-28	Pharmacia & Upjohn Ab	Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
BE1008491A3 (en) *	1994-07-14	1996-05-07	Croix Rouge De Belgique Depart	Sequence factor viii polypeptide antigenic, fragments and / or epitopes thereof.
EP0788375A2 (en)	1994-11-09	1997-08-13	Robin Ewart Offord	Functionalized polymers for site-specific attachment
EP0776530A4 (en) *	1995-06-21	1998-06-10	Motorola Inc	Method and antenna for providing an omnidirectional pattern
WO1997003195A1 (en)	1995-07-11	1997-01-30	Chiron Corporation	Novel factor viii:c polypeptide analogs with altered protease sites
SE9503380D0 (en)	1995-09-29	1995-09-29	Pharmacia Ab	Protein derivatives
AT403438B (en)	1996-05-24	1998-02-25	Immuno Ag	PHARMACEUTICAL PREPARATION WITH FACTOR VIII PROCOAGULATION ACTIVITY AND VWF BINDING ACTIVITY
US6458563B1 (en) *	1996-06-26	2002-10-01	Emory University	Modified factor VIII
EP0964702B1 (en) *	1996-08-02	2006-10-04	Ortho-McNeil Pharmaceutical, Inc.	Polypeptides having a single covalently bound n-terminal water-soluble polymer
CA2225189C (en)	1997-03-06	2010-05-25	Queen's University At Kingston	Canine factor viii gene, protein and methods of use
EP1881005B1 (en)	1997-07-14	2013-04-03	Bolder Biotechnology, Inc.	Derivatives of G-CSF and related proteins
WO2000042175A1 (en)	1999-01-14	2000-07-20	Bolder Biotechnology Inc.	Methods for making proteins containing free cysteine residues
US6753165B1 (en) *	1999-01-14	2004-06-22	Bolder Biotechnology, Inc.	Methods for making proteins containing free cysteine residues
CA2306629A1 (en) *	1997-10-17	1999-04-29	Harvest Technologies Corporation	Precipitation of growth-factor-enriched fibrinogen concentrate from platelet rich plasma
EP0922446A1 (en)	1997-12-03	1999-06-16	Applied Research Systems Ars Holding N.V.	Solution-phase site-specific preparation of GRF-PEG conjugates
PT1079805E (en)	1998-04-27	2005-03-31	Opperbas Holding Bv	PHARMACEUTICAL COMPOSITION UNDERSTANDING FACTOR VIII AND NEUTRAL LIPOSOMES
US6759216B1 (en)	1998-11-06	2004-07-06	Emory University	Glycosylated, low antigenicity low immunogenicity factor VIII
ATE372382T1 (en)	1998-11-10	2007-09-15	Sanquin Bloedvoorziening	A FACTOR VIII POLYPEPTIDE WITH FACTOR VIII:C ACTIVITY
US6136599A (en)	1998-12-10	2000-10-24	Bayer Corporation	Human hybrid host cell for mammalian gene expression
US6358703B1 (en)	1998-12-10	2002-03-19	Bayer Corporation	Expression system for factor VIII
EP1183354A2 (en)	1999-05-24	2002-03-06	The American National Red Cross	Methods of reducing factor viii clearance and compositions therefor
PT1257295E (en) *	2000-02-11	2009-07-16	Bayer Healthcare Llc	Factor vii or viia-like molecules
EP1319016A4 (en)	2000-09-19	2006-05-10	Univ Emory	MODIFIED FACTOR VIII
JP2005518181A (en)	2001-01-12	2005-06-23	ジ・アメリカン・ナショナル・レッド・クロス	Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
JP2004529640A (en) *	2001-03-22	2004-09-30	ノボノルディスクヘルスケアアクチェンゲゼルシャフト	Coagulation factor VII derivative
WO2002096454A1 (en)	2001-05-31	2002-12-05	D. Collen Research Foundation Vzw	Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
WO2002098454A2 (en)	2001-05-31	2002-12-12	D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven	Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
AU2002310438B2 (en)	2001-06-14	2008-05-01	The Scripps Research Institute	Stabilized proteins with engineered disulfide bonds
DE60230456D1 (en)	2001-10-05	2009-01-29	Expression Therapeutics Llc	FACTOR VIII POLYPEPTIDES AT HIGH EXPRESSION LEVEL AND METHOD OF USE
ATE412671T1 (en)	2002-04-18	2008-11-15	Merck Patent Gmbh	MODIFIED FACTOR VIII
JP4412461B2 (en)	2002-11-20	2010-02-10	日油株式会社	Modified bio-related substance, production method thereof and intermediate
US8003117B2 (en)	2002-11-20	2011-08-23	Nof Corporation	Polyalkylene glycol derivative and modified bio-related substance
WO2004060965A2 (en)	2002-12-31	2004-07-22	Nektar Therapeutics Al, Corporation	Hydrolytically stable maleimide-terminated polymers
US7329721B2 (en)	2002-12-31	2008-02-12	Nektar Therapeutics Al, Corporation	Maleamic acid polymer derivatives and their bioconjugates
MXPA05007348A (en)	2003-01-06	2005-10-05	Nektar Therapeutics Al Corp	Thiol-selective water-soluble polmer derivatives.
PT1596887T (en)	2003-02-26	2022-04-14	Nektar Therapeutics	Polymer-factor viii moiety conjugates
US20040180054A1 (en)	2003-03-13	2004-09-16	Hanmi Pharm. Co., Ltd.	Physiologically active polypeptide conjugate having prolonged in vivo half-life
US20050176108A1 (en)	2003-03-13	2005-08-11	Young-Min Kim	Physiologically active polypeptide conjugate having prolonged in vivo half-life
CN1820024B (en)	2003-05-12	2011-06-22	阿费麦克斯公司	Novel poly(ethylene glycol) modified compounds and uses thereof
US7887789B2 (en)	2003-05-23	2011-02-15	Nektar Therapeutics	Polymer derivatives having particular atom arrangements
EP1502921A1 (en)	2003-07-29	2005-02-02	ZLB Behring GmbH	Recombinant mutated human factor VIII (FVIII) with improved stability
EP1682106A4 (en)	2003-10-30	2008-06-11	Univ Emory	MODIFIED FVIII FACTOR WITH REDUCED IMMUNOGENICITY THROUGH MUTAGENESIS OF A2 AND C2 EPITOPES
US7211559B2 (en)	2003-10-31	2007-05-01	University Of Maryland, Baltimore	Factor VIII compositions and methods
US7855274B2 (en)	2003-12-03	2010-12-21	University Of Rochester	Recombinant factor VIII having increased specific activity
WO2006027111A1 (en)	2004-09-06	2006-03-16	Zlb Behring Gmbh	Modified coagulation factor viii with enhanced stability
PT2363414T (en)	2004-11-12	2022-08-04	Bayer Healthcare Llc	Site-directed modification of fviii
EP1871801A2 (en)	2005-04-01	2008-01-02	Novo Nordisk Health Care AG	Blood coagulation fviii analogues
KR20080108147A (en)	2006-03-31	2008-12-11	백스터 인터내셔널 인코포레이티드	Pegylated Factor ＶＩＩＩ
US7645860B2 (en)	2006-03-31	2010-01-12	Baxter Healthcare S.A.	Factor VIII polymer conjugates

2005
- 2005-11-14 PT PT111533006T patent/PT2363414T/en unknown
- 2005-11-14 HU HUE11153297A patent/HUE059193T2/en unknown
- 2005-11-14 PL PL11153297.4T patent/PL2371856T3/en unknown
- 2005-11-14 RU RU2007121517/10A patent/RU2423380C2/en active
- 2005-11-14 KR KR1020137007423A patent/KR101468345B1/en not_active Expired - Fee Related
- 2005-11-14 PT PT161869011T patent/PT3130601T/en unknown
- 2005-11-14 PT PT111532974T patent/PT2371856T/en unknown
- 2005-11-14 LT LTEP05849392.5T patent/LT1824988T/en unknown
- 2005-11-14 CN CN201610201090.XA patent/CN105753968A/en active Pending
- 2005-11-14 EP EP11153297.4A patent/EP2371856B1/en active Active
- 2005-11-14 KR KR1020127028644A patent/KR20120136413A/en not_active Ceased
- 2005-11-14 EP EP17166910.4A patent/EP3243833B1/en active Active
- 2005-11-14 DK DK11153300.6T patent/DK2363414T3/en active
- 2005-11-14 ES ES11153300T patent/ES2930159T3/en active Active
- 2005-11-14 SI SI200532309T patent/SI2371856T1/en unknown
- 2005-11-14 NZ NZ555032A patent/NZ555032A/en unknown
- 2005-11-14 MX MX2014005051A patent/MX350293B/en unknown
- 2005-11-14 UA UAA200706559A patent/UA95225C2/en unknown
- 2005-11-14 HU HUE05849392A patent/HUE033776T2/en unknown
- 2005-11-14 PL PL05849392T patent/PL1824988T3/en unknown
- 2005-11-14 LT LTEP11153300.6T patent/LT2363414T/en unknown
- 2005-11-14 MX MX2017007144A patent/MX392760B/en unknown
- 2005-11-14 NO NO20210454A patent/NO20210454A1/en unknown
- 2005-11-14 KR KR1020187027821A patent/KR20180110192A/en not_active Ceased
- 2005-11-14 DK DK05849392.5T patent/DK1824988T3/en active
- 2005-11-14 EP EP16186901.1A patent/EP3130601B1/en active Active
- 2005-11-14 HR HRP20180481AA patent/HRP20180481B1/en active IP Right Grant
- 2005-11-14 AU AU2005304622A patent/AU2005304622B2/en active Active
- 2005-11-14 KR KR1020147018134A patent/KR101654011B1/en not_active Expired - Fee Related
- 2005-11-14 BR BR122016022033A patent/BR122016022033B8/en active IP Right Grant
- 2005-11-14 DK DK11153297.4T patent/DK2371856T3/en active
- 2005-11-14 KR KR1020147002721A patent/KR101483917B1/en active Active
- 2005-11-14 PL PL11153300.6T patent/PL2363414T3/en unknown
- 2005-11-14 HU HUE16186901A patent/HUE050542T2/en unknown
- 2005-11-14 US US11/273,896 patent/US7632921B2/en active Active
- 2005-11-14 EP EP17201672.7A patent/EP3323829B1/en active Active
- 2005-11-14 HR HRP20070268AA patent/HRP20070268B1/en active IP Right Grant
- 2005-11-14 SI SI200532283T patent/SI3130601T1/en unknown
- 2005-11-14 ES ES16186901T patent/ES2821832T3/en active Active
- 2005-11-14 CN CN2005800464698A patent/CN101124331B/en active Active
- 2005-11-14 CN CN201510612184.1A patent/CN105148287B/en not_active Expired - Fee Related
- 2005-11-14 ES ES05849392.5T patent/ES2633916T3/en active Active
- 2005-11-14 EP EP05849392.5A patent/EP1824988B1/en active Active
- 2005-11-14 HU HUE11153300A patent/HUE060016T2/en unknown
- 2005-11-14 CN CN201610838893.6A patent/CN107082806A/en active Pending
- 2005-11-14 KR KR1020167023706A patent/KR101904630B1/en not_active Expired - Fee Related
- 2005-11-14 JP JP2007541405A patent/JP2008524117A/en active Pending
- 2005-11-14 CA CA2586379A patent/CA2586379C/en active Active
- 2005-11-14 ES ES11153297T patent/ES2930143T3/en active Active
- 2005-11-14 NO NO20200044A patent/NO345800B1/en unknown
- 2005-11-14 EP EP11153300.6A patent/EP2363414B1/en active Active
- 2005-11-14 PT PT58493925T patent/PT1824988T/en unknown
- 2005-11-14 CN CN201310125428.4A patent/CN103214569B/en active Active
- 2005-11-14 WO PCT/US2005/041205 patent/WO2006053299A2/en active Search and Examination
- 2005-11-14 CN CN201210455152.1A patent/CN103102406B/en active Active
- 2005-11-14 BR BRPI0517795A patent/BRPI0517795B8/en active IP Right Grant
- 2005-11-14 SI SI200532308T patent/SI2363414T1/en unknown
- 2005-11-14 EP EP16186902.9A patent/EP3153181A1/en not_active Withdrawn
- 2005-11-14 EP EP14165736.1A patent/EP2772500B1/en not_active Revoked
- 2005-11-14 LT LTEP16186901.1T patent/LT3130601T/en unknown
- 2005-11-14 LT LTEP11153297.4T patent/LT2371856T/en unknown
- 2005-11-14 MX MX2007005466A patent/MX2007005466A/en active IP Right Grant
- 2005-11-14 SI SI200532158T patent/SI1824988T1/en unknown
- 2005-11-14 KR KR1020077013131A patent/KR101243564B1/en active Active
- 2005-11-14 EP EP17170687.2A patent/EP3243834A1/en not_active Withdrawn
2007
- 2007-05-01 IL IL182903A patent/IL182903A/en active IP Right Grant
- 2007-05-08 ZA ZA200703696A patent/ZA200703696B/en unknown
- 2007-05-11 HN HN2007015683A patent/HN2007015683A/en unknown
- 2007-06-06 MA MA29972A patent/MA29663B1/en unknown
- 2007-06-12 NO NO20072997A patent/NO344606B1/en unknown
2009
- 2009-08-13 US US12/540,703 patent/US9364520B2/en active Active
2012
- 2012-10-19 JP JP2012231926A patent/JP6109523B2/en active Active
2013
- 2013-01-24 US US13/748,983 patent/US9096656B2/en active Active
2014
- 2014-02-12 PH PH12014500352A patent/PH12014500352B1/en unknown
- 2014-05-11 IL IL232540A patent/IL232540A/en active IP Right Grant
- 2014-09-02 IL IL23443314A patent/IL234433B/en active IP Right Grant
2015
- 2015-02-09 JP JP2015022993A patent/JP6018238B2/en active Active
- 2015-07-20 US US14/803,677 patent/US20160051633A1/en not_active Abandoned
2016
- 2016-12-02 JP JP2016234756A patent/JP6487895B2/en not_active Expired - Fee Related
- 2016-12-02 JP JP2016234757A patent/JP6559642B2/en not_active Expired - Fee Related
2017
- 2017-07-14 CY CY20171100753T patent/CY1119292T1/en unknown
2019
- 2019-05-07 BE BE2019C523C patent/BE2019C523I2/nl unknown
- 2019-05-07 HU HUS1900026C patent/HUS1900026I1/en unknown
- 2019-05-07 FR FR19C1031C patent/FR19C1031I2/en active Active
- 2019-05-08 LU LU00118C patent/LUC00118I2/fr unknown
- 2019-05-09 LT LTPA2019509C patent/LTC1824988I2/en unknown
- 2019-05-10 CY CY2019024C patent/CY2019024I1/en unknown
- 2019-05-10 NL NL300989C patent/NL300989I2/en unknown
- 2019-07-09 PH PH12019501613A patent/PH12019501613A1/en unknown
2020
- 2020-10-05 CY CY20201100928T patent/CY1123384T1/en unknown

Also Published As

Publication number	Publication date
CN107082806A (en)	2017-08-22
CN101124331A (en)	2008-02-13
UA95225C2 (en)	2011-07-25
PT1824988T (en)	2017-07-21
EP3243833A1 (en)	2017-11-15
PT2371856T (en)	2022-08-12
KR20130036780A (en)	2013-04-12
LUC00118I1 (en)	2019-05-13
ES2930143T3 (en)	2022-12-07
EP2371856A3 (en)	2012-03-14
IL232540A0 (en)	2014-06-30
US20130274445A1 (en)	2013-10-17
HK1117875A1 (en)	2009-01-23
PL1824988T3 (en)	2018-01-31
EP3243833B1 (en)	2020-06-17
HUE060016T2 (en)	2023-01-28
US20160051633A1 (en)	2016-02-25
FR19C1031I1 (en)	2019-06-28
EP3243834A1 (en)	2017-11-15
HRP20180481B1 (en)	2022-02-18
EP3323829A1 (en)	2018-05-23
HN2007015683A (en)	2011-07-11
ZA200703696B (en)	2008-08-27
BRPI0517795A (en)	2008-10-21
JP2008524117A (en)	2008-07-10
JP2017105773A (en)	2017-06-15
SI3130601T1 (en)	2020-11-30
EP2371856B1 (en)	2022-05-18
EP2371856A2 (en)	2011-10-05
EP2363414A3 (en)	2012-03-21
RU2007121517A (en)	2008-12-20
DK1824988T3 (en)	2017-08-07
PH12019501613A1 (en)	2020-09-14
JP6487895B2 (en)	2019-03-20
IL182903A0 (en)	2007-08-19
KR101904630B1 (en)	2018-10-04
KR101654011B1 (en)	2016-09-05
BR122016022033B1 (en)	2021-03-02
US7632921B2 (en)	2009-12-15
KR20070110260A (en)	2007-11-16
US20100081615A1 (en)	2010-04-01
HUS1900026I1 (en)	2022-04-28
CN101124331B (en)	2013-04-24
PT3130601T (en)	2020-10-01
BRPI0517795B8 (en)	2021-05-25
PL2363414T3 (en)	2022-09-05
KR101243564B1 (en)	2013-03-27
PL2371856T3 (en)	2022-08-22
PH12014500352A1 (en)	2015-07-20
KR20120136413A (en)	2012-12-18
CN103102406A (en)	2013-05-15
PT2363414T (en)	2022-08-04
HK1182121A1 (en)	2013-11-22
NL300989I1 (en)	2019-05-22
PH12014500352B1 (en)	2019-09-25
EP1824988A2 (en)	2007-08-29
EP2363414B1 (en)	2022-05-18
CY1123384T1 (en)	2021-12-31
WO2006053299A2 (en)	2006-05-18
HUE033776T2 (en)	2018-01-29
EP3130601A1 (en)	2017-02-15
CA2586379A1 (en)	2006-05-18
JP6559642B2 (en)	2019-08-14
KR20140091618A (en)	2014-07-21
EP3323829B1 (en)	2020-07-15
LT1824988T (en)	2017-10-25
ES2821832T3 (en)	2021-04-27
LT2371856T (en)	2022-08-25
JP6018238B2 (en)	2016-11-02
HUE050542T2 (en)	2020-12-28
HRP20180481A2 (en)	2018-06-29
EP3153181A1 (en)	2017-04-12
CA2586379C (en)	2012-04-03
AU2005304622A1 (en)	2006-05-18
NL300989I2 (en)	2019-11-28
CN105148287A (en)	2015-12-16
JP2017101028A (en)	2017-06-08
KR101468345B1 (en)	2014-12-03
FR19C1031I2 (en)	2020-06-05
NO20072997L (en)	2007-06-27
BRPI0517795A8 (en)	2018-12-26
KR101483917B1 (en)	2015-01-16
CN103214569A (en)	2013-07-24
ES2633916T3 (en)	2017-09-26
AU2005304622B2 (en)	2012-03-29
LTPA2019509I1 (en)	2019-08-26
NO345800B1 (en)	2021-08-09
JP6109523B2 (en)	2017-04-05
MX2007005466A (en)	2007-10-19
HUE059193T2 (en)	2022-10-28
NO344606B1 (en)	2020-02-10
WO2006053299A3 (en)	2006-08-24
LTC1824988I2 (en)	2021-02-25
IL182903A (en)	2014-09-30
EP3130601B1 (en)	2020-07-15
DK2371856T3 (en)	2022-08-08
BE2019C523I2 (en)	2025-02-10
NO20200044A1 (en)	2007-06-27
CY1119292T1 (en)	2018-02-14
BR122016022033B8 (en)	2021-05-25
RU2423380C2 (en)	2011-07-10
CN105753968A (en)	2016-07-13
ES2930159T3 (en)	2022-12-07
US20060115876A1 (en)	2006-06-01
SI2371856T1 (en)	2022-09-30
JP2013067621A (en)	2013-04-18
EP1824988A4 (en)	2008-12-31
CY2019024I2 (en)	2019-11-27
US9096656B2 (en)	2015-08-04
EP1824988B1 (en)	2017-04-19
US9364520B2 (en)	2016-06-14
MX392760B (en)	2025-03-24
KR20140019489A (en)	2014-02-14
LT3130601T (en)	2020-09-10
CY2019024I1 (en)	2019-11-27
HRP20070268B1 (en)	2018-04-20
KR20180110192A (en)	2018-10-08
HRP20070268A2 (en)	2007-09-30
LUC00118I2 (en)	2019-12-27
LT2363414T (en)	2022-10-25
HK1218718A1 (en)	2017-03-10
IL232540A (en)	2017-08-31
CN105148287B (en)	2019-07-09
MX350293B (en)	2017-09-04
SI1824988T1 (en)	2017-11-30
IL234433B (en)	2019-11-28
NO20210454A1 (en)	2007-06-27
SI2363414T1 (en)	2022-09-30
BRPI0517795B1 (en)	2020-03-31
EP2772500B1 (en)	2019-12-25
CN103102406B (en)	2015-05-27
EP2772500A1 (en)	2014-09-03
CN103214569B (en)	2016-12-28
KR20160105928A (en)	2016-09-07
NZ555032A (en)	2010-02-26
MA29663B1 (en)	2008-08-01
EP2363414A2 (en)	2011-09-07
JP2015134780A (en)	2015-07-27

Publication	Publication Date	Title
DK2363414T3 (en)	2022-08-08	Site-directed modification of FVIII
DK1802579T3 (en)	2014-01-20	Derivatives of 3-arylaminopyridine
DK1992697T3 (en)	2010-05-17	Preparation of TNFR-Fc
DK1778618T3 (en)	2014-03-10	Synthesis of triethylenetetramines
DE602005012267D1 (en)	2009-02-26	N OF DEVICES
DK2377869T3 (en)	2014-04-14	Synthesis of Bortezomib
DK1720866T3 (en)	2011-11-21	Course of action
DK1745062T3 (en)	2014-08-11	Enhanced modulators of coagulation factors
DK1940465T3 (en)	2012-10-22	New use of anti-IL-1beta antibodies
DE602005013349D1 (en)	2009-04-30	OPTICAL SILICON COMPONENT
DK1587542T3 (en)	2012-07-30	Use of anti-CD100 antibodies
NO20043305D0 (en)	2004-08-09	Preparation of lodixanol
DK1763520T3 (en)	2009-02-09	Use of trisubstituted benzopyranones
FI20040603A0 (en)	2004-04-28	Highchair
DK2301576T3 (en)	2012-12-10	Therapeutic use of anti-CS1 antibodies
FR2877833B1 (en)	2007-10-12	CORRECTEUR OF LORDOSES
DK1730109T3 (en)	2008-09-29	Synthesis of pyrrole-2-carbonitriles
DE602005020393D1 (en)	2010-05-20	Adhesive plaster
AT6947U3 (en)	2005-03-25	BOB
FI20041183L (en)	2006-03-14	Integrated lens
AT7051U3 (en)	2005-03-25	BOB
DK1787450T3 (en)	2014-09-22	Selection of information
DK1968641T3 (en)	2014-08-11	PREPARATION OF CONJUGATES
ITMI20041764A1 (en)	2004-12-16	MULTIFUNCTIONAL GARMENT
FI20040602A0 (en)	2004-04-28	Highchair